Akkermansia muciniphila — Microbiome Interpretation

In laboratory settings, it breaks down mucin and may support mucus turnover. Stool-based tests report it as a proportion of detected bacteria; species-level calls from 16S assays can be less precise than shotgun metagenomics.

What studies report

Individual scientific claims about this species, one per row. Each entry stands on its own—no synthesis required. Weak and emerging findings sit alongside stronger ones, so the full picture accumulates without waiting for a formal review.

Date	Source	Claim	Type	Confidence	Notes
2013	Everard et al., PNAS	Lower A. muciniphila abundance associated with obesity and metabolic dysfunction in mice; oral administration improved metabolic markers	association	med	Animal model; direction replicated in other preclinical work
2017	Depommier et al., Nature Medicine	Pasteurized A. muciniphila supplementation associated with improved insulin sensitivity and reduced fat mass in overweight adults	intervention	med	Small RCT; not equivalent to interpreting consumer test abundance
2021	Multiple cohort meta-analyses	Lower relative abundance frequently reported in type 2 diabetes and obesity cohorts across populations	association	med	Observational; heterogeneity between studies and methods
ongoing	Various	Single low abundance reading on a stool test indicates need for specific probiotic or diet	hypothesis	low	Not supported for individual clinical decisions from one snapshot

Reported associations

Observed associations between abundance shifts and health markers or biological outcomes. Direction and study context matter more than any single reading on a test report.

Species	Direction	Outcome	Context	Evidence strength	Source
A. muciniphila	↑	Improved insulin sensitivity	Overweight/obese adults, pasteurized supplementation trial	moderate	Depommier et al., 2017
A. muciniphila	↓	Metabolic dysfunction markers	Obesity and T2D observational cohorts	moderate	Multiple human cohort studies
A. muciniphila	↑	Mucus layer thickness / barrier-related markers	Preclinical models	moderate	Mechanistic rodent studies
A. muciniphila	↔	Individual symptom resolution	Consumer microbiome reports	weak	Insufficient evidence for causal claims

Reported interventions

Dietary, supplemental, and other factors reported to shift abundance of this species. An association here does not mean that changing your level will produce the listed effect.

Intervention	Effect on species	Evidence level	Study type	Notes
Dietary fiber increase	↑ abundance (variable)	moderate	Observational and short intervention studies	Response differs by fiber type and baseline microbiome
Polyphenol-rich foods (e.g., cranberries, grapes)	↑ abundance in some trials	low–moderate	Small human and animal studies	Not all studies show consistent effect
Metformin	↑ abundance reported in some T2D cohorts	low–moderate	Observational and mechanistic	Confounded by disease and diet
Pasteurized A. muciniphila supplement	↑ detectable effects on host markers; colonization variable	moderate	RCT	Research product, not general consumer guidance

What not to conclude from your test

That you have or will develop a specific disease because Akkermansia is “low” or “high”
That you need a particular probiotic, prebiotic, or restrictive diet
That your result explains symptoms on its own
That a change between two tests proves your intervention worked